Moderna, Inc.: COVID-19 trials

The registry lists 24 COVID-19 studies with Moderna, Inc. as lead sponsor. 3 are open to participants now and 5 have results posted.

Phase 1 1Phase 2 5Phase 3 5Phase 4 4No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing FormulationsNot yet recruitingNCT07863635Phase 4
• A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of AgeNot yet recruitingNCT07808697Phase 2
• A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsRecruitingNCT06585241Phase 4
• A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated AdultsCompletedNCT06354998Phase 3Results posted
• A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19CompletedNCT05815498Phase 3Results posted
• Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in InfantsTerminatedNCT05584202Phase 2Results posted
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine BoostersCompletedNCT05137236Phase 2Results posted
• A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19CompletedNCT04649151Phase 2/3Results posted
• A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)Active, not recruitingNCT07266558Phase 4
• A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsCompletedNCT07089706Phase 4
• A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeCompletedNCT06864143Phase 2
• Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeCompletedNCT06694389Phase 3
• Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGEActive, not recruitingNCT06333704
• A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)Active, not recruitingNCT06189053
• Post-marketing Safety of Elasomeran/Davesomeran and AndusomeranCompletedNCT06130345
• A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 VaccineCompletedNCT06113692
• A Study of the Effectiveness of Moderna COVID-19 VaccineCompletedNCT05933304
• Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19CompletedNCT05894590
• Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 VaccineCompletedNCT05894525
• Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19CompletedNCT05894499
• An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)CompletedNCT05765578
• A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeCompletedNCT05436834Phase 3
• A Study of Modified mRNA Vaccines in Healthy AdultsCompletedNCT05397223Phase 1
• Long-Term Follow-up Survey of COVID-19 Vaccine After VaccinationCompletedNCT04941144